+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leishmaniasis (Kala-Azar) (Infectious Disease) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • 139 Pages
  • September 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5451315
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide, 'Leishmaniasis - Drugs In Development, 2021', provides an overview of the Leishmaniasis (Infectious Disease) pipeline landscape. Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights


This latest pipeline guide provides comprehensive information on the therapeutics under development for Leishmaniasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. The Leishmaniasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 14, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3, 16 and 10 molecules, respectively.

The Leishmaniasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leishmaniasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leishmaniasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Infectious Disease)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Leishmaniasis (Kala-Azar) - Overview

Leishmaniasis (Kala-Azar) - Therapeutics Development

Leishmaniasis (Kala-Azar) - Therapeutics Assessment

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development

Leishmaniasis (Kala-Azar) - Drug Profiles

Leishmaniasis (Kala-Azar) - Dormant Projects

Leishmaniasis (Kala-Azar) - Discontinued Products

Leishmaniasis (Kala-Azar) - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Leishmaniasis (Kala-Azar), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by ABIONYX Pharma SA, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Acea Biotech Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Biokawthar Technologies SAS, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by DetectoGen Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Eisai Co Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by GlaxoSmithKline Plc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Immune Modulation Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Impetis Biosciences Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Macrophage Therapeutics Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by MedC Biopharma Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Mind Medicine MindMed Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Molecular Targeting Technologies Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Mycosynthetix Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by NanoCliq LLC, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Pai Life Sciences Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Pfizer Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Pharos I&BT Co Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Rakta Therapeutics Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Satellos Bioscience Inc, 2021
  • Leishmaniasis (Kala-Azar) - Pipeline by Synstar Japan Co Ltd, 2021
  • Leishmaniasis (Kala-Azar) - Dormant Projects, 2021
  • Leishmaniasis (Kala-Azar) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Leishmaniasis (Kala-Azar), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ABIONYX Pharma SA
  • Acea Biotech Inc
  • Biokawthar Technologies SAS
  • BioLingus AG
  • Daiichi Sankyo Co Ltd
  • DetectoGen Inc
  • Eisai Co Ltd
  • GlaxoSmithKline Plc
  • Immune Modulation Inc
  • Impetis Biosciences Ltd
  • Macrophage Therapeutics Inc
  • ManRos Therapeutics
  • Matinas BioPharma Holdings Inc
  • MedC Biopharma Ltd
  • Mind Medicine MindMed Inc
  • Molecular Targeting Technologies Inc
  • Mycosynthetix Inc
  • NanoCliq LLC
  • Nanomerics Ltd
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Pai Life Sciences Inc
  • Pfizer Inc
  • Pharos I&BT Co Ltd
  • Rakta Therapeutics Inc
  • Satellos Bioscience Inc
  • Synstar Japan Co Ltd